Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the ...

A new drug has shown promise as a type 2 diabetes and weight loss treatment—potentially offering an new rival to drugs like Ozempic. Ecnoglutide—a new once-weekly GLP-1 receptor agonist injection ...

An FDA database analysis shows that reported adverse skin events after GLP-1 receptor agonist use are rare but can include rash and pruritus, highlighting a need for further research, according to a ...

Estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults. (HealthDay News) — For older adults with type 2 diabetes, the risk for dementia ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide is approved by the FDA for slowing the progression of chronic kidney disease. Liraglutide and ...

Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects ...